STERIS (NYSE:STE) Director Sells $310,284.31 in Stock

June 5, 2026 by InsiderTrades.com

Key Points

Insider sale: STERIS Director Richard Breeden sold 1,481 shares on June 2 for about $310,284, reducing his direct stake by 3.66%.
Quarterly results were mixed: The company reported $2.83 EPS, slightly below estimates, while revenue of $1.59 billion matched expectations and rose 6.7% year over year.
Dividend and analyst outlook: STERIS declared a $0.63 quarterly dividend and analysts currently have a Moderate Buy consensus with a $278 average price target.

STERIS plc (NYSE:STE - Get Free Report) Director Richard Breeden sold 1,481 shares of the company's stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $209.51, for a total value of $310,284.31. Following the completion of the sale, the director directly owned 38,964 shares in the company, valued at $8,163,347.64. This trade represents a 3.66% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

STERIS Stock Up 0.9%

STERIS stock opened at $212.09 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.54 and a current ratio of 2.09. The firm has a market capitalization of $20.70 billion, a price-to-earnings ratio of 26.74 and a beta of 0.93. STERIS plc has a fifty-two week low of $195.14 and a fifty-two week high of $269.44. The stock's fifty day moving average is $217.48 and its two-hundred day moving average is $239.28.

STERIS (NYSE:STE - Get Free Report) last posted its earnings results on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share for the quarter, missing the consensus estimate of $2.86 by ($0.03). The firm had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.59 billion. STERIS had a net margin of 13.18% and a return on equity of 14.15%. The firm's revenue for the quarter was up 6.7% on a year-over-year basis. During the same period last year, the company posted $2.74 EPS. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. Analysts predict that STERIS plc will post 11.18 EPS for the current fiscal year.

STERIS Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 26th. Shareholders of record on Monday, June 8th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Monday, June 8th. This represents a $2.52 annualized dividend and a yield of 1.2%. STERIS's dividend payout ratio is 31.78%.

Analysts Set New Price Targets

Several research firms have weighed in on STE. Weiss Ratings lowered STERIS from a "hold (c+)" rating to a "hold (c)" rating in a report on Wednesday, May 27th. Wall Street Zen raised STERIS from a "buy" rating to a "strong-buy" rating in a report on Saturday, May 16th. Piper Sandler reaffirmed an "overweight" rating and set a $270.00 price objective on shares of STERIS in a research note on Thursday, May 21st. Finally, KeyCorp decreased their price objective on STERIS from $291.00 to $269.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 13th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, STERIS presently has a consensus rating of "Moderate Buy" and a consensus price target of $278.00.

Check Out Our Latest Analysis on STERIS

Hedge Funds Weigh In On STERIS

Several large investors have recently added to or reduced their stakes in the business. NewEdge Advisors LLC lifted its position in STERIS by 2.1% during the first quarter. NewEdge Advisors LLC now owns 8,062 shares of the medical equipment provider's stock worth $1,783,000 after buying an additional 168 shares during the period. Glenmede Trust Co. NA lifted its position in STERIS by 12.2% during the first quarter. Glenmede Trust Co. NA now owns 4,120 shares of the medical equipment provider's stock worth $911,000 after buying an additional 447 shares during the period. Segall Bryant & Hamill LLC lifted its position in STERIS by 5.2% during the first quarter. Segall Bryant & Hamill LLC now owns 19,159 shares of the medical equipment provider's stock worth $4,237,000 after buying an additional 940 shares during the period. Groupe la Francaise raised its holdings in shares of STERIS by 9.4% in the 1st quarter. Groupe la Francaise now owns 18,514 shares of the medical equipment provider's stock worth $4,094,000 after purchasing an additional 1,589 shares during the period. Finally, Western Wealth Management LLC purchased a new position in shares of STERIS in the 1st quarter worth about $25,000. 94.69% of the stock is currently owned by hedge funds and other institutional investors.

STERIS Company Profile

(Get Free Report)

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.